01:39 , May 4, 2019 |  BioCentury  |  Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
07:00 , Oct 7, 2013 |  BC Week In Review  |  Company News

BioMarker Strategies management update

BioMarker Strategies LLC , Baltimore, Md.   Business: Cancer, Diagnostic   Hired: Jerry Parrott as president, CEO and a director, formerly VP of corporate communications and public policy at Human Genome Sciences Inc. , which...
07:00 , Sep 2, 2013 |  BioCentury  |  Strategy

Back to School: Facing Reality

BC Staff  For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Company News

Merck KGaA cancer news

Merck KGaA (Xetra:MRK), Darmstadt, Germany   Business: Cancer   Merck's EMD Serono Inc. subsidiary announced the creation of an "immuno-oncology (iONC) innovation platform" to integrate research, early-stage development and biomarker strategies to develop cancer immunotherapies....
07:00 , May 27, 2013 |  BioCentury  |  Finance

Value reality check

Europe's economic crisis has created a new reality. Austerity measures at the national level have placed an even higher premium than in the past on controlling healthcare costs, resulting in an increasingly tough reimbursement environment...
08:00 , Feb 4, 2013 |  BioCentury  |  Finance

Analyst tracks

Analyst tracks David Maris joined BMO Capital Markets as a managing director covering specialty pharmaceuticals. He is the founder of financial advisory firm Phalanx Partners. He was an equity research analyst at CLSA from 2009-11....
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

BioMarker Strategies board of directors update

BioMarker Strategies LLC , Baltimore, Md.   Business: Cancer, Diagnostic   Appointed: Jack Davis as executive chairman, formerly chairman and CEO of Dianon Systems Inc. , which Laboratory Corp. of America Holdings acquired  ...
07:00 , Mar 24, 2011 |  BC Innovations  |  Tools & Techniques

Aspiring cancer diagnostic

Massachusetts researchers have developed portable NMR technology that uses fine needle aspirates to help scientists diagnose cancer more quickly and accurately than is possible with conventional tumor biopsies. 1 Although the technology could confirm the...